Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Uniflu with Vitamin C
- Development stage
- Unknown
- Lead developer
- Phoenix Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Uniflu with Vitamin C is an over-the-counter (OTC) combination medication developed by Phoenix Laboratories for the symptomatic relief of the common cold and influenza. The product is formulated as a dual-tablet system consisting of a multi-active tablet (containing paracetamol, diphenhydramine hydrochloride, phenylephrine hydrochloride, and caffeine) and a separate vitamin C (ascorbic acid) tablet. Paracetamol acts as an analgesic and antipyretic to reduce pain and fever; phenylephrine hydrochloride is a decongestant that relieves nasal and sinus congestion; diphenhydramine hydrochloride is an antihistamine that alleviates runny nose and sneezing while suppressing cough; caffeine is a mild central nervous system stimulant included to counteract drowsiness; and vitamin C serves as an antioxidant supplement to support immune recovery. It is approved and marketed in Ireland and Malta.
- Brand names
- Uniflu with Gregovite 'C'Uniflu with Vitamin C
- Other names
- caffeine + diphenhydramine + paracetamol + phenylephrine + vitamin Ccaffeine + diphenhydramine hydrochloride + paracetamol + phenylephrine hydrochloride + ascorbic acidcaffeine + diphenhydramine hydrochloride + paracetamol + phenylephrine hydrochloride + vitamin Cparacetamol + caffeine + diphenhydramine hydrochloride + phenylephrine hydrochloride + ascorbic acidparacetamol + caffeine + diphenhydramine hydrochloride + phenylephrine hydrochloride + vitamin C
02
Targets
ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HRH1 (Histamine H1 Receptor)ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)CHRM4 (M4)CHRM5 (M5)
Beyond the preview
Go deeper on Uniflu with Vitamin C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Uniflu with Vitamin C.